David Risinger
Stock Analyst at Leerink Partners
(4.53)
# 267
Out of 5,147 analysts
178
Total ratings
67.35%
Success rate
15.04%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Outperform | $305 → $355 | $379.33 | -6.41% | 6 | Feb 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Outperform | $54 → $60 | $61.10 | -1.80% | 5 | Jan 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $480.13 | +9.35% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $28.49 | +12.32% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $26.76 | +68.16% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $1,022.02 | +8.02% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $6.84 | +338.60% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $69.22 | +1.13% | 4 | Oct 14, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $243.47 | -37.16% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $770.79 | +8.20% | 9 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $206 | $224.69 | -8.32% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $23.93 | +188.34% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $11.75 | +36.17% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $34.32 | +28.21% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $60.00 | +155.00% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $18.19 | -45.02% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $56.11 | -16.24% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $26.77 | -58.91% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $143.77 | -36.70% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $27.10 | +77.12% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $7.23 | +411.76% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $188.97 | -6.86% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $15.25 | +4.92% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $14.19 | +217.12% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.04 | +479.47% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $26.19 | +56.55% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $129.76 | +34.09% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $45.36 | +12.43% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $33.77 | -76.31% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $119.30 | -25.40% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $14.49 | -79.30% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $30.73 | -47.93% | 9 | Apr 2, 2020 |
Amgen
Feb 4, 2026
Maintains: Outperform
Price Target: $305 → $355
Current: $379.33
Upside: -6.41%
Bristol-Myers Squibb Company
Jan 13, 2026
Maintains: Outperform
Price Target: $54 → $60
Current: $61.10
Upside: -1.80%
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $480.13
Upside: +9.35%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $28.49
Upside: +12.32%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $26.76
Upside: +68.16%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $1,022.02
Upside: +8.02%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $6.84
Upside: +338.60%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $69.22
Upside: +1.13%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $243.47
Upside: -37.16%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $770.79
Upside: +8.20%
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $224.69
Upside: -8.32%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $23.93
Upside: +188.34%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $11.75
Upside: +36.17%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $34.32
Upside: +28.21%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $60.00
Upside: +155.00%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $18.19
Upside: -45.02%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $56.11
Upside: -16.24%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $26.77
Upside: -58.91%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $143.77
Upside: -36.70%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $27.10
Upside: +77.12%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $7.23
Upside: +411.76%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $188.97
Upside: -6.86%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $15.25
Upside: +4.92%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $14.19
Upside: +217.12%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.04
Upside: +479.47%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $26.19
Upside: +56.55%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $129.76
Upside: +34.09%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $45.36
Upside: +12.43%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $33.77
Upside: -76.31%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $119.30
Upside: -25.40%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $14.49
Upside: -79.30%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $30.73
Upside: -47.93%